Last reviewed · How we verify

NCT06282029

ACT-group for Stroke Survivors (Pilot Study)

Completed NA Last updated 8 August 2025
What this trial tests

NA trial testing Group Therapy in Stroke in 10 participants. Completed in 11 February 2025.

Timeline
1 February 2024
Primary endpoint
16 July 2024
11 February 2025

Quick facts

Lead sponsorBielefeld University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment10
Start date1 February 2024
Primary completion16 July 2024
Estimated completion11 February 2025
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Bielefeld University

Who can join

18 and older, any sex, with Stroke or Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical pilot trial is to test the feasibility, acceptance and preliminary efficacy of an adapted group psychotherapy manual in stroke survivors with psychological stress. The main questions it aims to answer are: * Is the group therapy feasible? * Is the group therapy accepted by stroke survivors and therapists? * Are there first indications on the efficacy of the group therapy to improve mental health? Participants will take part in 8 weekly group therapy sessions of 90 minutes each.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Group Therapy

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Bielefeld University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing